Ann: Appendix 4E and FY24 Full Year Statutory Accounts, page-13

The whole Generic's Strategy that started back in 2015, was based initially on Efinaconazole. At the time a US$200M plus seller. We were told that ACR won the Patent court case in 2017. But seeing it's now 7 years since that win, and not a single Pharma Company has been allowed to launch a Generic, it feels more like a loss. Anywhere from $2-4 million was spent developing this ANDA, and to date has earned nothing. And an equal amount was spent developing a Axion Generic, was launched briefly then was pulled. That's anywhere form $4 to $7M spent on 2 ANDA's with sweet FA to show for it. Jet